Literature DB >> 3427318

Biochemical picture accompanying sclerotic bone metastases of prostatic origin.

S Minisola1, G Perugia, A Scarda, L Scarnecchia, D Tuzzolo, W Rossi, G Mazzuoli.   

Abstract

This study was carried out to evaluate the metabolic consequences of osteosclerotic skeletal metastases of prostatic origin in a homogeneous group of patients. We found significantly increased mean values of serum alkaline phosphatase activity and significantly reduced mean values of serum phosphate, 24-h urinary calcium, fasting calcium excretion and TmP/GFR in cancer patients with respect to age-matched controls. Mean serum immunoreactive parathyroid hormone (iPTH) levels were raised, with two patients showing increased values of the hormone above our normal limits. Our findings indicate that mild secondary hyperparathyroidism is a feature of these patients. However, it cannot be excluded that both the reduced serum phosphate and TmP/GFR values may be related, at least in some cases, to the effects of the tumour itself on tubular reabsorption of phosphate.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3427318     DOI: 10.1111/j.1464-410x.1987.tb05011.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  3 in total

1.  Refractory hypocalcaemia complicating metastatic prostatic carcinoma.

Authors:  Christopher Rizzo; Sandro Vella; Mario J Cachia
Journal:  BMJ Case Rep       Date:  2015-06-29

2.  Mineral metabolism abnormalities in patients with prostate cancer: a systematic case controlled study.

Authors:  Francesco Minisola; Cristiana Cipriani; Luciano Colangelo; Mirella Cilli; Alessandro Sciarra; Magnus Von Heland; Luciano Nieddu; Emanuela Anastasi; Roberto Pascone; Valeria Fassino; Daniele Diacinti; Flavia Longo; Salvatore Minisola; Jessica Pepe
Journal:  Endocrine       Date:  2017-06-28       Impact factor: 3.633

3.  Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases.

Authors:  A A G Bryden; J A Hoyland; A J Freemont; N W Clarke; N J R George
Journal:  Br J Cancer       Date:  2002-02-01       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.